DEA proposal would improve access to DaTscan

Michael Walter | | Radiology Business | Policy & Regulations

A recent proposal by the Drug Enforcement Administration (DEA) would give more physicians access to [123l]lofupane (DaTscan), a diagnostic agent that helps make dopamine transporters in the brain visible and could lead to more accurate diagnoses of Parkinson’s.

In its Notice of Proposed Rulemaking (NPRM), the DEA proposed that DaTscan be removed from Schedule II of the Controlled Substances Act (CSA).

“The DEA finds that the facts and all available and relevant data demonstrate that [123I]ioflupane does not possess abuse or dependence potential,” the text of the NPRM said. “Accordingly, the DEA finds that [123I]ioflupane does not meet the requirements for inclusion in any schedule and should be removed from control under the CSA.”

According to the American College of Radiology (ACR)--which advocated for DaTscan’s removal from the CSA--this will improve access to this “important” agent, improving the overall quality of patient care.

This pdf from 2009 from the FDA provides more information about DaTscan.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Physician Medicare pay fix in jeopardy following criticism from Donald Trump, Elon Musk
Blue Cross Blue Shield affiliate rejects MRI contrast coverage, labeling it ‘investigational’
Radiologists push governor to veto bill that would produce ‘staggering’ increase in liability premiums
Radiology experts say state Medicaid rates must increase to improve imaging access
Policy reforms in Washington that will impact nuclear imaging
U.S. moves closer to establishing domestic supply of Mo-99 for nuclear imaging

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.